Proposed changes for haematology conditions

Additions in bold, deletions in strikethrough:

Initial application — (thrombotic thrombocytopenic purpura (TTP)*) only from a haematologist or any relevant Ppractitioner on the recommendation of a haematologist. Approvals valid for without further renewal unless notified 8 weeks for applications meeting the following criteria:

BothAll of the following:

1. The total rituximab dose used per cycle would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks; and
2. Each treatment cycle at least 6 months apart; and
3. Either
   1. Patient has thrombotic thrombocytopenic purpura* and has experienced progression of clinical symptoms or persistent thrombocytopenia despite plasma exchange; or
   2. Patient has acute idiopathic thrombotic thrombocytopenic purpuraTTP* with neurological or cardiovascular pathology.

Note: Indications marked with * are unapproved indications.

---

Renewal — (thrombotic thrombocytopenic purpura (TTP)*) \only from a haematologist or Practitioner on the recommendation of a haematologist. Approvals valid for 8 weeks for applications meeting the following criteria.

All of the following:

1. Patient was previously treated with rituximab for thrombotic thrombocytopenic purpura*; and
2. An initial response lasting at least 12 months was demonstrated; and
3. Patient now requires repeat treatment; and
4. The total rituximab dose used would not exceed the equivalent of 375 mg/m2 of body surface area per week for a total of 4 weeks

Note: Indications marked with * are unapproved indications.